BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1627-1629

  Simara, Pavel ^a   Peterkova, Martina ^a   Stejskal, Stanislav ^a   Potesilova, Michaela ^a   Koutna, Irena ^a   Racil, Zdenek ^c   Razga, Filip ^c   Jurcek, Tomas ^c   Dvorakova, Dana ^b,c   Mayer, Jiri ^b,c  

^a Faculty of Informatics   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CRK LIKE PROTEIN; IMATINIB; NILOTINIB;

CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LETTER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84864257067     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.656104     Document Type: Letter

References (15)

1. D aley G, Van Etten R, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830.
2. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
3. G abert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of " real-time " quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-2357.
4. B hatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707.
5. Nichols G, Raines M, Vera J, et al. Identifi cation of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994;84:2912-2918.
6. P atel H, Marley S, Gordon M. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes Cancer 2006;45: 1121-1129.
7. White D, Saunders V, Lyons A, et al. In vitro sensitivity to imatinibinduced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520-2526.
8. L ucas C, Harris R, Giannoudis A, et al. BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. Br J Haematol 2010;149:458-460.
9. K horashad J, Wagner S, Greener L, et al. Th e level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica 2009;94:861-864.
10. Racil Z, Razga F, Buresova L, et al. Th e assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is aff ected by the proportion of diff erent cells types in the analyzed cell population. Am J Hematol 2010;85:525-528.
11. H amilton A, Elrick L, Myssina S, et al. BCR-ABL activity and its response to drugs can be determined in CD34- CML stem cells by CrkL phosphorylation status using fl ow cytometry. Leukemia 2006;20: 1035-1039.
12. S okal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in " good-risk " chronic granulocytic leukemia. Blood 1984;63:789-799.
13. Hasford J, Pfi rrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858.
14. Engler J, Frede A, Saunders V, et al. Chronic myeloid leukemia CD34- cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010;24:765-770.
15. Engler JR, Frede A, Saunders V, et al. Th e poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34- cells. Blood 2010;116: 2776-2778.